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Objective To examine the relationship between dietary
supplement use during pregnancy and birth outcomes.
Design A prospective birth cohort.
Setting Leeds, UK.
Sample One thousand two hundred and seventy-four pregnant
women aged 18–45 years.
Methods Dietary supplement intake was ascertained using three
questionnaires for the ﬁrst, second and third trimesters. Dietary
intake was reported in a 24-hour dietary recall administered by a
research midwife at 8–12 weeks of gestation. Information on
delivery details and antenatal pregnancy complications was
obtained from the hospital maternity records.
Main outcome measures Birthweight, birth centile and preterm
birth.
Results Reported dietary supplement use declined from 82% of
women in the ﬁrst trimester of pregnancy to 22% in the
second trimester and 33% in the third trimester. Folic acid was
the most commonly reported supplement taken. Taking any
type of daily supplement during any trimester was not
signiﬁcantly associated with size at birth taking into account
known relevant confounders. Women taking multivitamin-
mineral supplements in the third trimester were more likely to
experience preterm birth (adjusted OR = 3.4, 95% CI 1.2, 9.6,
P = 0.02).
Conclusions Regular multivitamin–mineral supplement use during
pregnancy, in a developed country setting, is not associated with
size at birth. However, it appears to be associated with preterm
birth if taken daily in the third trimester. The mechanism for this
is unclear and our study’s ﬁndings need conﬁrming by other
cohorts and/or trials in developed countries.
Keywords Birthweight, dietary supplements, pregnancy, pregnancy
outcome, preterm birth.
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Introduction
Multivitamin–mineral supplements during pregnancy are
becoming an attractive option considered by international
agencies to improve the nutritional status of pregnant
women in developing countries. They are considered rela-
tively cheap, feasible and have the potential to improve
maternal nutrition when administered through national
antenatal programmes. However, dietary supplements are
not subject to the same rigorous safety and efﬁcacy stan-
dards as prescription medications.
1 Their proposed use
during pregnancy is supported by ﬁndings from several
randomised controlled trials in developing country settings,
where deﬁciency in micronutrients is more prevalent. Stud-
ies in Nepal, India, Indonesia, Guinea-Bissau and Tanzania
have shown positive effects on adverse birth outcomes such
as infant mortality and low birthweight.
2–6 However, other
trials in Nepal, Mexico and Zimbabwe have failed to dem-
onstrate a signiﬁcant effect on the incidence of low birth-
weight,
7–10 and some have even demonstrated an increased
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10,11 According to a Cochrane sys-
tematic review, there is currently insufﬁcient evidence to
suggest replacement of iron and folate supplementation
with multiple micronutrient supplements and further
research is needed to quantify the degree of maternal or
fetal beneﬁt and to assess the risk of excess supplementa-
tion and the potential for adverse interactions between the
micronutrients.
12
Although multivitamin supplements have been recom-
mended for women who might become pregnant in some
developed countries, such as the USA,
13 there are few stud-
ies examining their effect on birth outcomes in developed
countries, where there is likely to be a signiﬁcant difference
in women’s baseline nutrient status compared with devel-
oping countries. A randomised controlled trial in France
showed signiﬁcant positive effects for micronutrient supple-
mentation versus placebo on the incidence of low birth-
weight.
14 However, this study had a relatively small sample
size of 100 women and a very small number of babies born
with low birthweight. The supplements given in this study
were iron-free and so differ from currently available over-
the-counter multivitamin–mineral preparations for preg-
nant women. There was no difference detected in the oxi-
dative stress parameters measured in the study between
supplemented and unsupplemented women.
The Camden study on the impact of multivitamin sup-
plementation on pregnancy was conducted in a disadvan-
taged urban setting in the USA.
15 Risks of both low
birthweight and preterm delivery were signiﬁcantly reduced
with supplement use in the ﬁrst and second trimester.
Analysis was restricted to data obtained by 28 weeks of ges-
tation and the relationship between infant outcomes and
supplement use in the third trimester of pregnancy was not
reported.
We therefore analysed observational data collected for a
large prospective cohort study, the Caffeine and Reproduc-
tive Health (CARE) birth cohort in Leeds, UK, to examine
the relationship between supplement use during the ﬁrst,
second and third trimesters of pregnancy and two out-
comes: birthweight and preterm delivery.
Methods
Participants
Women aged 18–45 years with low-risk pregnancies were
prospectively recruited at 8–12 weeks of gestation from the
Leeds Teaching Hospitals maternity unit between 2003 and
2006 as part of a multicentre prospective study into mater-
nal diet and birth outcomes. The inclusion criteria and the
methodology are described in detail elsewhere.
16,17 All
women participating in the study gave informed written
consent and the study was approved by the Leeds West
Local Research Ethics Committee.
Assessment of diet and supplement use
Supplement use was ascertained throughout pregnancy
using questionnaires in the ﬁrst, second and third trimes-
ters. The questionnaires were interviewer-administered
during the ﬁrst trimester (up to 12 weeks of gestation)
and third trimester (from 28 weeks of gestation) and self-
administered during the second trimester (13–27 weeks of
gestation). In the third trimester, the interviews were per-
formed retrospectively on a sub-sample of the cohort fol-
lowing a nested case–control design (n = 425) with a
ratio of 2:1. The respondents were asked to report the
type/brand, frequency and amount of all the dietary sup-
plements they were using during each trimester. The
questions were free text rather than multiple choice ques-
tions, asking participants to tick the type of supplements
they were using to ensure all sources were covered. The
supplement types were then coded during data entry.
Dietary intake was reported in a 24-hour dietary recall
administered by a research midwife at 8–12 weeks of
gestation.
Assessment of pregnancy outcomes
Information was obtained from the hospital maternity
records on antenatal pregnancy complications and delivery
details (gestational age at delivery, birthweight and sex of
the baby). We analysed birthweight as the primary out-
come measure in two forms: as a continuous variable in
grams and as expressed on customised centile charts that
took into account maternal height, weight, ethnicity and
parity, and neonatal birthweight and sex.
18 We examined
preterm birth, deﬁned as delivery at <37 weeks of gesta-
tion, as a secondary outcome measure.
Statistical power calculations
Comparing birthweights between supplement users and
nonusers within the ﬁrst trimester, using the ratios of users
to nonusers and standard deviations identiﬁed in the
study, we had 80% power to detect a difference of 120 g;
90% power to detect a difference of 140 g, for P < 0.05.
Within trimester 2, we had 80% power to detect a differ-
ence of <115 g; 90% power to detect a difference of 130 g.
Within trimester 3, we had 85% power to detect a dou-
bling of the prevalence of babies born less than the tenth
centile (from 13% to 26%), and to detect a tripling of the
preterm birth rate (from 5% to 15%) for a two-sided test
at P < 0.05.
Statistical methods
We performed univariable analyses using two-sample Stu-
dent’s t-tests for continuous variables and chi-square tests
for categorical variables. We used multiple linear regression
for continuous outcomes and logistic regression for binary
outcomes.
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small-for-gestational-age and preterm births, and general
linear modelling for birthweight and customised birth
centile using STATA version 10.
19 Maternal age, height,
weight, ethnicity and parity at booking and neonatal gesta-
tion at delivery and baby’s sex were taken into account in
the deﬁnition for customised birth centile, and were
adjusted for in the model for birthweight. We also made
statistical adjustment for salivary cotinine levels, self-
reported alcohol consumption, maternal age, maternal veg-
etarian diet, Index of Multiple Deprivation (IMD) score,
the mother having a university degree, past history of mis-
carriage and long-term chronic illness in all models. The
IMD 2007 combines a number of indicators (chosen to
cover a range of economic, social and housing issues) into
a single deprivation score for each small area in England.
This allows each area to be ranked relative to one another
according to their level of deprivation.
20 Sensitivity analyses
were performed taking into account clinical diagnosis of
intrauterine growth restriction (IUGR) in the models.
With regards to the exposure of interest, analysis was
performed using two groups; women who reported taking
any type of daily supplements and those who speciﬁcally
reported taking multivitamin–mineral supplements during
pregnancy.
Results
Characteristics of women in supplement-taking
and nonsupplement-taking groups
The total number of participants was 1274. All had infor-
mation on supplement intake in the ﬁrst and second tri-
mester; 425 women had information on supplement intake
in the third trimester. The proportion of pregnant women
taking any form of daily supplements was 82%, 22% and
33% for the ﬁrst, second and third trimesters, respectively
(Table 1). Women who reported taking supplements at any
stage of pregnancy were more likely to have a university
degree and be vegetarian, and less likely to be smokers.
They were less likely to be living in an area with an IMD
score in the most deprived quartile. Women who reported
taking daily supplements in the ﬁrst and second trimester
were more likely to be primiparous. However, there was no
difference between primiparous and multiparous women in
their use of supplements in the third trimester. There were
also no differences between women who reported taking
daily supplements at any stage in pregnancy from those
who did not with regards to prepregnancy weight, ethnic
origin or history of long-term illness. Out of the women
who took daily supplements in the third trimester
(n = 139), 94% (n = 131) also reported taking daily sup-
plements in the ﬁrst trimester of their pregnancy and 66%
(n = 91) took daily supplements in their second trimester.
Only ﬁve women who reported taking daily supplements in
the third trimester had not taken supplements in the ﬁrst
or second trimester.
Dietary recall
Based on midwife-administered 24-hour recall dietary
assessment at 8–12 weeks of gestation, women in our
cohort had average dietary intakes from food above the ref-
erence nutrient intake values for most vitamins and miner-
als
21 except vitamin D, iron, folate, selenium and iodine
(Table 2). The table shows the mean intake in our cohort,
the nutrient requirements for adult women plus the addi-
tional requirement recommended for consumption during
pregnancy, and the proportion of the women in our cohort
with dietary intakes above the recommended reference
nutrient intake in pregnancy. The mean total energy intake
was 2125 kcal/day (95% CI 2084, 2166).
Type of supplements
Women reported taking 22 different types of supplements
including folic acid, iron, combined folic acid–iron prepa-
rations, multivitamin–mineral preparations (six brands),
evening primrose, cod liver oil, omega 3, vitamin C, vita-
min B, vitamin D, vitamin E, vitamin A, calcium, zinc,
magnesium and selenium preparations (Table 3). Folic acid
was the most frequently reported daily supplement in the
ﬁrst trimester. Multivitamin–mineral supplements were the
most frequently reported daily supplements in the third tri-
mester.
Birth outcomes
Birthweight was known for 1259 babies. The mean birth-
weight was 3439 g (95% CI 3397, 3461). 4.4% weighed
<2500 g (n = 55). 13% (n = 166) weighed less than the
tenth centile, 8% (n = 99) less than the ﬁfth centile and
5% (n = 65) less than the third centile. 9% (n = 118)
weighed more than the 90th centile. Out of the 1234
pregnancies with information on gestational age, 55 (4.5%)
delivered before 37 weeks of gestation.
Relationship between supplement taking and
birthweight
Using a multiple linear regression model, taking any type of
daily supplement during the ﬁrst, second or third trimester
of pregnancy was not associated with the customised birth
centile as a measure of birth size (adjusted difference 2.7,
95% CI: 2.5, 7.8, P = 0.3 for the ﬁrst trimester; 3.2, 95% CI:
0.9, 7.4, P = 0.1 for the second trimester; and 0.5, 95% CI:
6.0, 7.0, P = 0.9 for the third trimester) when adjusting for
cotinine levels, self-reported alcohol intake, IMD group,
having a university degree (39%), mother being a vegetarian
(9%), history of long-term chronic illness (13%) and past
history of miscarriage (24%).
Dietary supplement use in pregnancy and birth outcome
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for the above factors as well as maternal age, height, ethnic-
ity, prepregnancy weight, parity, gestational age and baby’s
sex, there was also no relationship between taking daily
supplements at any stage in pregnancy and birthweight
(adjusted difference 6 g, 95% CI: 70, 82, P = 0.9 for the
ﬁrst trimester, 24 g, 95% CI: 36, 83, P = 0.4 for the second
trimester, and )7 g, 95% CI: 106, 91, P = 0.9 for the third
trimester).
When we looked at taking particular types of supple-
ments, taking a daily multivitamin–mineral preparation at
any stage in pregnancy was not associated with size at birth
using the continuous outcomes of birthweight in grams
and customised birth centile, as well as the binary outcome
of small-for-gestational-age (less than tenth centile)
(Table 4). It was not associated with having a baby weigh-
ing less than the third centile (adjusted OR = 1.5, 95% CI
0.8, 2.7, P = 0.3 for the ﬁrst trimester, 1.2, 95% CI 0.5, 2.6,
P = 0.7 for the second trimester, 1.6, 95% CI 0.7, 3.7,
P = 0.3 for the third trimester). There were no associations
with having a baby weighing less than the ﬁfth centile or
more than the 90th centile. In addition, taking iron-con-
Table 2. Average daily intakes of vitamins and minerals (from diet alone) based on 24-hour dietary recall at 8–12 weeks of pregnancy, Leeds,
UK, 2003–06 (n = 1257)
Micronutrient Mean (SD) RNI* Recommended
increment to RNI
during pregnancy**
Proportion of
women with intakes
above the pregnancy
RNI (95% CI)
Thiamin (mg/day) 2.4 (7.7) 0.8 +0.1 85 (83, 87)
Riboﬂavin (mg/day) 1.7 (0.8) 1.1 +0.3 58 (55, 61)
Niacin (mg/day) 20 (10) 13 – 75 (72, 77)
Vitamin B6 (mg/day) 2.1 (1.0) 1.2 – 85 (82, 86)
Vitamin B12 (lg/day) 3.9 (3.7) 1.5 – 79 (77, 82)
Folate (lg/day) 257 (119) 200 +100 32 (29, 35)
Vitamin C (lg/day) 143 (129) 40 +10 75 (73, 78)
Vitamin A (lg retinol
equivalent/day)
803 (665) 600 +100 45 (42, 48)
Vitamin D (lg/day) 2.5 (2.7) – 10 2 (1, 3)
Vitamin E (mg/day) 7.9 (5.4) – **** –
Calcium (mg/day) 938 (471) 700 *** 65 (62, 68)
Phosphorus (mg/day) 1344 (501) 550 *** 98 (97, 99)
Magnesium (mg/day) 283 (112) 270 *** 49 (46, 52)
Iron (mg/day) 11.5 (5.3) 14.8 *** 20 (18, 23)
Zinc (mg/day) 8.6 (4.3) 7 *** 59 (56, 62)
Copper (mg/day) 1.1 (0.6) 1.2 *** 32 (29, 35)
Selenium (lg/day) 58 (37) 60 *** 40 (38, 43)
Iodine (lg/day) 118 (82) 140 *** 28 (24, 29)
*Reference nutrient intakes (RNI) for women aged 19–50 years in the UK.
21
**Reference nutrient intakes for pregnant women.
21
***No increment.
21
****Safe intake – above 3 mg/day for women.
21
Table 3. Number of women taking different types of supplements
during pregnancy
Supplement First
trimester
Second
trimester
Third
trimester
Folic acid 845 51 2
Iron 8 21 29
Folic acid/iron 2 1 1
Multivitamin-mineral 293 177 79
Evening primrose 6 2 2
Cod liver oil 10 2 3
Omega 3 ﬁsh oil 11 12 9
Vitamin C 18 8 15
Vitamin B 7 0 2
Vitamin E 1 3 1
Vitamin A 0 0 1
Calcium 14 8 3
Zinc 7 1 1
Magnesium 2 0 0
Selenium 2 0 0
Dietary supplement use in pregnancy and birth outcome
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associated with size at birth (data not shown).
Relationship between supplement taking and
preterm birth
We used a logistic regression model to examine the relation-
ship between the risk of preterm birth and patterns of sup-
plement-taking during pregnancy adjusting for salivary
cotinine levels, self-reported alcohol intake, vegetarian diet,
ethnicity, maternal age, baby’s sex, parity, IMD score, having
a university degree, past history of miscarriage and long-term
chronic illness. Any type of daily supplement-taking during
the third trimester was associated with an increase in the risk
of preterm birth (adjusted OR 3.0, 95% CI 1.2, 7.4,
P = 0.02). This relationship was not statistically signiﬁcant
for supplement-taking in the second trimester (adjusted OR
1.6, 95% CI 0.8, 3.2, P = 0.2) and was marginally signiﬁcant
in the ﬁrst trimester, although conﬁdence intervals were wide
(adjusted OR 4.3, 95% CI 1.0, 18.2, P = 0.05).
Taking multivitamin–mineral supplement preparations
during the third trimester was also associated with an
increased risk of preterm birth (adjusted OR 3.4, 95% CI
1.2, 9.6, P = 0.02). This relationship was not statistically
signiﬁcant in the ﬁrst or second trimester (Table 4). When
looking at any iron-containing supplement, the relationship
remained signiﬁcant only for supplement-taking in the
third trimester (adjusted OR 3.0, 95% CI 1.2, 7.6,
P = 0.02).
Sensitivity analyses
In addition, we adjusted for the clinical diagnosis of IUGR
detected by ultrasound scan during pregnancy and docu-
mented in the maternity notes, in the relationship between
taking a multivitamin–mineral supplement preparation and
both birthweight and preterm birth. The risk of preterm
birth when taking supplements in the third trimester
(adjusted OR 3.5, 95% CI 1.2, 10.0, P = 0.02) remained
broadly unchanged.
To take into account the possibility that the pattern of
multivitamin–mineral supplement use is inﬂuenced by pre-
vious adverse birth outcomes, we also performed the same
analysis separately by parity. In primiparous women, the
adjusted OR for the relationship between taking multivita-
min–mineral supplement in the third trimester and pre-
term birth was 5.4 (95% CI 1.3, 22.7, P = 0.02). In
multiparous women, the adjusted OR was 3.7 (95% CI 0.5,
29.4, P = 0.2). However, numbers were small with resulting
wide conﬁdence intervals.
Table 4. The relationship between maternal multivitamin-mineral supplement use during pregnancy and birth outcomes, Leeds, UK, 2003–06
Daily multivitamin–mineral supplements Unadjusted
difference (95% CI)
P value Adjusted
difference (95% CI)
P value
Birthweight (g)
First trimester 30.0 ()45.7, 105.7) 0.5 *16.9 ()42.3, 75.8) 0.7
Second trimester 38.4 ()53.6, 130.5) 0.4 29.4 ()43.0, 101.5) 0.3
Third trimester )29.1 ()179.9, 121.6) 0.7 )50.4 ()168.7, 67.9) 0.4
Customised birth centile
First trimester 3.6 ()0.2, 7.5) 0.06 **1.8 ()2.3, 5.9) 0.4
Second trimester 5.1 (0.4, 9.7) 0.04 3.3 ()1.8, 8.3) 0.3
Third trimester 1.2 ()6.5, 8.8) 0.8 )2.3 ()10.3, 5.7) 0.8
Small for gestational age (<10th centile)
First trimester 1.0 (0.6, 1.4) 0.8 1.3 (0.8, 1.9) 0.3
Second trimester 0.9 (0.5, 1.4) 0.6 1.1 (0.7, 1.9) 0.7
Third trimester 0.7 (0.4, 1.3) 0.3 0.9 (0.5, 1.7) 0.8
Preterm birth (<37 weeks)
First trimester 0.9 (0.5, 1.8) 0.8 ***1.3 (0.6, 2.7) 0.5
Second trimester 1.0 (0.5, 2.2) 0.9 1.8 (0.8, 4.1) 0.2
Third trimester 1.8 (0.8, 4.4) 0.2 3.4 (1.2, 9.6) 0.02
*Adjusted for gestational age, baby’s sex, maternal age, height, prepregnancy weight, ethnicity, parity, salivary cotinine levels, self-reported alco-
hol intake, past history of miscarriage, long-term chronic illness, index of multiple deprivation (IMD) score, educational attainment and maternal
vegetarian diet in a multiple linear regression model.
**Adjusted for salivary cotinine levels, self-reported alcohol intake, past history of miscarriage, long-term chronic illness, IMD score, educational
attainment and maternal vegetarian diet in a multiple linear regression model.
***Adjusted for salivary cotinine levels, self-reported alcohol intake, maternal age, maternal vegetarian diet, ethnicity, baby’s sex, parity, IMD
score, educational attainment, past history of miscarriage and long-term chronic illness in an unconditional logistic regression model.
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Our results show that taking daily multivitamin–mineral
supplements during any stage in pregnancy is not associated
with lower birthweight. However, taking multivitamin–
mineral supplements in the third trimester is associated
with a three-fold increased risk of preterm birth after
adjustment for smoking, alcohol intake and other relevant
maternal and socioeconomic factors. This effect seems
more pronounced in primiparous women. Although the
number of women taking supplements in the third trimes-
ter was considerably less than that for the ﬁrst two trimes-
ters, there was enough power with the nested case–control
design to detect an odds ratio of 3 for the preterm birth
outcome. However, this study is observational so causality
cannot be inferred from the ﬁndings. As we did not have
information on iatrogenic preterm birth, it is possible that
some women knew that they were at risk of preterm birth
and that this knowledge initiated physician or patient-led
supplementation. However, in our study, only ﬁve women
who reported taking daily supplements in the third trimes-
ter, did not take supplements in the ﬁrst and second tri-
mester. None of these ﬁve women had a preterm birth.
Because this is not a randomised controlled trial, we can-
not rule out the possibility that residual confounding may
be contributing to this apparent association. There may be
unmeasured confounders resulting in the apparent negative
relationship between multivitamin supplement taking in
the third trimester and preterm birth. However, we have
adjusted for most factors known to confound this relation-
ship. The possibility that supplement use may be inﬂu-
enced by a woman knowing that the baby is not growing
as would be expected is taken into account by adjusting for
the clinical diagnosis of IUGR, as extracted from the preg-
nancy medical notes, in a sensitivity analysis.
We have considered the potential that previous poor
pregnancy outcome may inﬂuence the mother’s decision to
take supplements in subsequent pregnancies and therefore,
adjusted for past history of miscarriage in the main models
and performed the analysis separately for primiparous and
multiparous women in a sensitivity analysis. The hypothesis
is that women with previous adverse pregnancy outcomes
would be more likely to take supplements as well as to
experience adverse outcomes in their subsequent pregnan-
cies. This would confound the relationship between supple-
ment-taking in the third trimester and preterm birth.
However, we found this relationship to be more pro-
nounced in primiparous women. This means that the effect
is not inﬂuenced by previous birth outcomes.
The use of multivitamin–mineral supplements in our
cohort was restricted mainly to two pregnancy-speciﬁc
brands. Both brands included folate and vitamin C exceed-
ing the current recommended minimum during pregnancy
(Table 2). One of the brands had the additional compo-
nents of B-carotene, vitamin K, selenium and iodine as well
as higher doses of vitamins E, B1, B6 and B12 and zinc (at
least double) compared with the other main brand.
Women in our cohort were receiving adequate amounts of
these micronutrients from their diet alone, as assessed by
the 24-hour dietary recall (Table 2), conﬁrming the inverse
supplement hypothesis, that women who least need supple-
ments are most likely to take them.
22
Other studies have suggested potential adverse effects of
some supplements, speciﬁcally those containing antioxidant
vitamins such as vitamins C and E, on pregnancy outcome
when taken by women with adequate dietary micronutrient
intake. Smedts et al.,
23 in a case–control study of offspring
with congenital heart disease, found that periconceptual
use of vitamin E supplements with high dietary intake of
the same vitamin was associated with up to nine-fold
increase in the risk of congenital heart disease. Another
study found that use of supplements for vitamins C and E
was associated with an increased risk of premature rupture
of membranes.
24 Unfortunately, this information was not
recorded in our study. In a randomised controlled trial to
assess the effect of vitamin E and C supplementation dur-
ing pregnancy on the incidence of pre-eclampsia, Poston
et al.
25 found that more low birthweight babies were born
to women who took these antioxidants than to controls. A
recent-meta-analysis of seven studies concluded that com-
bined vitamin C and E supplementation had no potential
beneﬁt in the improvement of maternal and neonatal out-
come and increased the risk of gestational hypertension in
women at risk of pre-eclampsia.
26
It is well established that there are signiﬁcant interactions
between micronutrients and their metabolism. It has been
shown in rats, for example, that copper deﬁciency during
pregnancy can result in reduced iron status and vice versa,
and that copper overload induces iron overload, by inter-
fering with the iron regulatory mechanism.
27,28 Others have
demonstrated interactions between iron and zinc.
29 During
the third trimester, fetal growth is at its most rapid. The
fetus not only needs minerals to sustain its growth, it is
also a stage when the fetal liver builds up stores for the
immediate postnatal period. A reduction in mineral avail-
ability, by interactions between the nutrients in the mater-
nal gut or liver or in the placenta itself, may result in
adverse outcomes for the baby.
The pattern of dietary supplement use in our cohort, with
most women taking supplements (mainly folic acid) in the
ﬁrst trimester, is expected because there is no national rec-
ommendation in England for routine supplement-taking
during pregnancy apart from folic acid in the ﬁrst trimester
and vitamin D for pregnant women in ‘high-risk’ groups.
30
There is no national recommendation to take multivitamin
and mineral supplements at any stage during pregnancy.
Dietary supplement use in pregnancy and birth outcome
ª 2010 The Authors Journal compilation ª RCOG 2010 BJOG An International Journal of Obstetrics and Gynaecology 827However, they are readily available over-the-counter and
are heavily promoted to expectant mothers. Health value
and susceptibility to illness are major predictors of supple-
ment use by women, with dietary supplements acting as an
insurance against possible ill health.
31
Implications for research
Most previous trials and observational studies in developed
country settings have looked at the effect of taking multivi-
tamin supplementation in early pregnancy on maternal and
birth outcomes. More research is needed into the effect of
taking multivitamin–mineral supplements in late pregnancy
on birth outcomes in relatively well-nourished populations.
Larger cohort studies are required to examine this associa-
tion in detail and to validate the ﬁndings of this study.
Results from our cohort also suggest that a trial in a devel-
oped country setting is needed to weigh the possible bene-
ﬁts and harms of policies recommending supplementation
or restriction of supplementation.
Implications for clinical practice
The study ﬁndings suggest that clinicians and midwives
should be cautious when recommending over-the-counter
multivitamin supplements to women in late pregnancy. As in
any clinical situation, they should weigh the potential risks
and beneﬁts when considering prescribing such supplements
during the third trimester of pregnancy. The type of supple-
ment recommended/prescribed should be more focused on
the speciﬁc vitamin/mineral deﬁciency the woman has.
Although the negative relationship between multivitamin
supplement-taking in the third trimester and preterm birth
needs to be investigated further, this study did not show any
positive effect on birthweight and gestational age when these
supplements are taken at any stage in pregnancy.
Conclusion
In this study, the use of multivitamin and mineral supple-
ment preparations during the third trimester in pregnancy
was associated with an increased risk of preterm delivery,
and was not associated with birthweight, small- or large-
for-gestational-age, at any stage in pregnancy. These ﬁnd-
ings suggest that, at least in micronutrient-replete mothers,
caution must be exercised when recommending multivita-
min–mineral supplements in late pregnancy. This is an
observational prospective study offering weaker causal evi-
dence than a randomised controlled trial. However, in the
absence of a trial in a developed country setting, this study
makes a useful contribution to the research evidence in this
area. The ﬁndings generate a concern regarding multivita-
min supplement use in late pregnancy that needs to be
investigated by other studies.
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